The PrecivityAD blood test from C2N Diagnostics significantly influences clinicians’ decisions about whether to treat people with cognitive impairments…
Articles by Lindsey Shapiro, PhD
Quest Diagnostics has launched a consumer-initiated blood test for adults in the U.S. that assesses Alzheimer’s disease risk…
Racial and ethnic minority groups in the U.S. are underrepresented in Alzheimer’s disease neuroimaging research, but the gap may…
A U.S. Food and Drug Administration (FDA) advisory committee has decided that data from the Phase 3 Clarity AD trial…
One year of treatment with ALZ-801 (valiltramiprosate) was found in a Phase 2 trial to improve cognition and lower…
The Phase 1 INTERCEPT-AD trial testing the investigational antibody ACU193 in patients with early Alzheimer’s disease has now…
A low dose of ACI-24.060, AC Immune’s investigational vaccine therapy, safely elicited the production of anti-amyloid beta antibodies among…
The U.S. Food and Drug Administration (FDA) has rejected Eli Lilly’s application for the accelerated approval of its amyloid-clearing antibody…
Note: This story was updated Feb. 7, 2023, to correct the number of participants in the Study 201 (NCT01767311), which evaluated…
The U.S. Food and Drug Administration (FDA) has cleared for use tests designed by Roche to measure the levels of…